Covered recipient · General Payments record
PETER MCALLISTER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$266,275.18
625 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $183,217.77 | 145 |
| Consulting Fee | $58,268.00 | 17 |
| Honoraria | $9,500.00 | 6 |
| Food and Beverage | $8,604.74 | 430 |
| Travel and Lodging | $6,673.51 | 26 |
| Education | $11.16 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
Page 3 of 13; records 101–150 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PETER MCALLISTER
NPI 1033176896 · CMS profile ID 1915
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
FAIRFIELD, CT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 13; records 101–150 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1033176896?year=2020&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PETER MCALLISTER, NPI 1033176896, CMS profile ID 1915. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 13; records 101–150 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033176896?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). PETER MCALLISTER, NPI 1033176896, CMS profile ID 1915. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 13; records 101–150 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033176896?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- PETER MCALLISTER, NPI 1033176896, CMS profile ID 1915, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 13; records 101–150 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1033176896?year=2020&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
625 matching records · $266,275.18 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 625.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.41 | 10/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727783755 | CMS |
| Janssen Pharmaceuticals, Inc | $1.87 | 10/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787403100 | CMS |
| Allergan, Inc. | $500.00 | 10/23/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275799 | CMS |
| Grifols USA, LLC | $23.05 | 10/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750413185 | CMS |
| Harmony Biosciences LLC | $21.39 | 10/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750464915 | CMS |
| Allergan, Inc. | $500.00 | 10/22/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275797 | CMS |
| MERZ NORTH AMERICA, INC. | $14.95 | 10/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737046171 | CMS |
| Allergan, Inc. | $14.52 | 10/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275795 | CMS |
| Amgen Inc. | $2,250.00 | 10/21/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741261605 | CMS |
| Biogen, Inc. | $20.16 | 10/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737277355 | CMS |
| Genentech USA, Inc. | $19.30 | 10/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743080879 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/21/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728581581 | CMS |
| Allergan, Inc. | $500.00 | 10/20/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275793 | CMS |
| CSL Behring | $15.61 | 10/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728952045 | CMS |
| Currax Pharmaceuticals LLC | $3.80 | 10/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739126613 | CMS |
| Eisai Inc. | $24.99 | 10/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751244863 | CMS |
| Lilly USA, LLC | $1,500.00 | 10/20/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728595457 | CMS |
| Allergan, Inc. | $500.00 | 10/19/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275791 | CMS |
| Neurocrine Biosciences, Inc. | $19.05 | 10/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748930967 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.77 | 10/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749545051 | CMS |
| Allergan, Inc. | $4.64 | 10/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275787 | CMS |
| Allergan, Inc. | $1,800.00 | 10/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275789 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728588423 | CMS |
| Allergan, Inc. | $500.00 | 10/15/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275785 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/15/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728588425 | CMS |
| Lundbeck LLC | $1,250.00 | 10/15/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747551613 | CMS |
| Merck Sharp & Dohme Corporation | $23.28 | 10/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747795613 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $11.67 | 10/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747263369 | CMS |
| Allergan, Inc. | $17.28 | 10/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275783 | CMS |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | $16.82 | 10/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747901207 | CMS |
| Allergan, Inc. | $500.00 | 10/13/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275781 | CMS |
| Kyowa Kirin, Inc. | $9.09 | 10/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746879645 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/13/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728598859 | CMS |
| Allergan, Inc. | $500.00 | 10/12/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275779 | CMS |
| Currax Pharmaceuticals LLC | $1.27 | 10/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739126599 | CMS |
| Currax Pharmaceuticals LLC | $12.51 | 10/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739126605 | CMS |
| Upsher-Smith Laboratories LLC | $15.23 | 10/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 733038947 | CMS |
| Allergan, Inc. | $10.91 | 10/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275777 | CMS |
| Lilly USA, LLC | $200.00 | 10/09/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728585069 | CMS |
| Teva Pharmaceuticals USA, Inc. | $2,160.00 | 10/09/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749517835 | CMS |
| Allergan, Inc. | $6.79 | 10/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275773 | CMS |
| Allergan, Inc. | $500.00 | 10/08/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275775 | CMS |
| GENZYME CORPORATION | $14.94 | 10/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744105771 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/08/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728581573 | CMS |
| Allergan, Inc. | $500.00 | 10/07/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275771 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.06 | 10/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749571607 | CMS |
| Allergan, Inc. | $1.30 | 10/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275767 | CMS |
| Allergan, Inc. | $500.00 | 10/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723275769 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728595455 | CMS |
| Lilly USA, LLC | $1,200.00 | 10/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728598857 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $5,128.13 | 9 |
| PY2025 | Principal investigator | $2,010,823.12 | 443 |
| PY2024 | Recipient | $9,120.00 | 1 |
| PY2024 | Principal investigator | $2,244,731.55 | 346 |
| PY2023 | Recipient | $36,295.26 | 9 |
| PY2023 | Principal investigator | $1,621,983.46 | 236 |
| PY2022 | Recipient | $962.00 | 3 |
| PY2022 | Principal investigator | $2,128,116.24 | 90 |
| PY2021 | Recipient | $3,258.80 | 6 |
| PY2021 | Principal investigator | $2,093,701.91 | 321 |
| PY2020 | Recipient | $2,622.45 | 2 |
| PY2020 | Principal investigator | $1,143,007.78 | 136 |
| PY2019 | Recipient | $19,905.66 | 7 |
| PY2019 | Principal investigator | $1,443,942.42 | 235 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
452 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202532264 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202533927 |
| Principal investigator 1 | ABBVIE INC. | $1,082.56 | 12/31/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202533931 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703118 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703212 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703292 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703294 |
| Principal investigator 1 | PFIZER INC. | $175.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703418 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703470 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703540 |
| Principal investigator 1 | PFIZER INC. | $700.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703708 |
| Principal investigator 1 | PFIZER INC. | $700.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703868 |
| Principal investigator 1 | PFIZER INC. | $3,136.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704026 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704118 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704184 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704268 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704340 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704344 |
| Principal investigator 1 | PFIZER INC. | $175.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704508 |
| Principal investigator 1 | PFIZER INC. | $3,136.00 | 12/31/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704522 |
| Principal investigator 1 | PFIZER INC. | $40.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703120 |
| Principal investigator 1 | PFIZER INC. | $218.40 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703194 |
| Principal investigator 1 | PFIZER INC. | $287.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703196 |
| Principal investigator 1 | PFIZER INC. | $164.50 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703198 |
| Principal investigator 1 | PFIZER INC. | $245.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703210 |
| Principal investigator 1 | PFIZER INC. | $341.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703284 |
| Principal investigator 1 | PFIZER INC. | $259.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703286 |
| Principal investigator 1 | PFIZER INC. | $318.50 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703288 |
| Principal investigator 1 | PFIZER INC. | $318.50 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703290 |
| Principal investigator 1 | PFIZER INC. | $245.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703366 |
| Principal investigator 1 | PFIZER INC. | $164.50 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703368 |
| Principal investigator 1 | PFIZER INC. | $294.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703370 |
| Principal investigator 1 | PFIZER INC. | $104.30 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703416 |
| Principal investigator 1 | PFIZER INC. | $287.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703472 |
| Principal investigator 1 | PFIZER INC. | $266.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703474 |
| Principal investigator 1 | PFIZER INC. | $313.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703476 |
| Principal investigator 1 | PFIZER INC. | $104.30 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703538 |
| Principal investigator 1 | PFIZER INC. | $350.70 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703546 |
| Principal investigator 1 | PFIZER INC. | $313.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703612 |
| Principal investigator 1 | PFIZER INC. | $259.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703614 |
| Principal investigator 1 | PFIZER INC. | $245.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703616 |
| Principal investigator 1 | PFIZER INC. | $338.10 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703618 |
| Principal investigator 1 | PFIZER INC. | $347.20 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703620 |
| Principal investigator 1 | PFIZER INC. | $287.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703706 |
| Principal investigator 1 | PFIZER INC. | $341.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703710 |
| Principal investigator 1 | PFIZER INC. | $338.10 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703714 |
| Principal investigator 1 | PFIZER INC. | $40.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703716 |
| Principal investigator 1 | PFIZER INC. | $217.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703786 |
| Principal investigator 1 | PFIZER INC. | $245.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703788 |
| Principal investigator 1 | PFIZER INC. | $313.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703870 |
| Principal investigator 1 | PFIZER INC. | $350.70 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703950 |
| Principal investigator 1 | PFIZER INC. | $313.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228703952 |
| Principal investigator 1 | PFIZER INC. | $341.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703954 |
| Principal investigator 1 | PFIZER INC. | $287.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704016 |
| Principal investigator 1 | PFIZER INC. | $245.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704120 |
| Principal investigator 1 | PFIZER INC. | $341.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704182 |
| Principal investigator 1 | PFIZER INC. | $266.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704192 |
| Principal investigator 1 | PFIZER INC. | $499.30 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704194 |
| Principal investigator 1 | PFIZER INC. | $245.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704342 |
| Principal investigator 1 | PFIZER INC. | $313.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704352 |
| Principal investigator 1 | PFIZER INC. | $287.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704356 |
| Principal investigator 1 | PFIZER INC. | $294.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704400 |
| Principal investigator 1 | PFIZER INC. | $313.60 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704402 |
| Principal investigator 1 | PFIZER INC. | $217.00 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704512 |
| Principal investigator 1 | PFIZER INC. | $499.30 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704582 |
| Principal investigator 1 | PFIZER INC. | $218.40 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704584 |
| Principal investigator 1 | PFIZER INC. | $347.20 | 12/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704764 |
| Principal investigator 1 | ABBVIE INC. | $25,592.00 | 12/04/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202528166 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293339 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293341 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293343 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293345 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293347 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293349 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293351 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 11/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293353 |
| Principal investigator 1 | H. Lundbeck A S | $3,817.10 | 11/20/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251777509 |
| Principal investigator 1 | PFIZER INC. | $11,853.71 | 11/20/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228817529 |
| Principal investigator 1 | Eli Lilly and Company | $3,000.00 | 11/17/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY | No dispute reported | 06/30/2026 | 1187886246 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $24,211.89 | 11/17/2025 | Non-covered Recipient Entity Ki Health Partners LLC | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647402 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $4,658.00 | 11/17/2025 | Non-covered Recipient Entity Ki Health Partners LLC | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647404 |
| Principal investigator 1 | Ipsen Innovation | $450.00 | 11/14/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289022 |
| Principal investigator 1 | ABBVIE INC. | $25,536.00 | 11/05/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202521361 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,000.00 | 10/31/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307147 |
| Principal investigator 1 | ABBVIE INC. | $9,723.00 | 10/30/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202519825 |
| Principal investigator 1 | ABBVIE INC. | $3,780.00 | 10/28/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1202518811 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293239 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293241 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293243 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293245 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293247 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293249 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293251 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293253 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293255 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293257 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293259 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293261 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293263 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293265 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293267 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293269 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293271 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293273 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293275 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 10/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293277 |
| Principal investigator 1 | Amgen Inc. | $12,888.00 | 10/23/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) | No dispute reported | 06/30/2026 | 1246643370 |
| Principal investigator 1 | H. Lundbeck A S | $4,741.45 | 10/23/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251776016 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703116 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703414 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703536 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703542 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703544 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228703784 |
| Principal investigator 1 | PFIZER INC. | $3,507.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704116 |
| Principal investigator 1 | PFIZER INC. | $700.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704180 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704354 |
| Principal investigator 1 | PFIZER INC. | $700.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704510 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704520 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 10/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC DBA New England Institute for Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704580 |
| Principal investigator 1 | Genentech, Inc. | $3,980.00 | 10/15/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211619899 |
| Principal investigator 1 | H. Lundbeck A S | $631.00 | 10/15/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775646 |
| Principal investigator 1 | H. Lundbeck A S | $2,625.00 | 10/15/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775650 |
| Principal investigator 1 | Ipsen Innovation | $270.00 | 10/14/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289018 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 10/14/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289020 |
| Principal investigator 1 | ABBVIE INC. | $56,973.00 | 10/09/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202515897 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $15,000.00 | 10/01/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647386 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,500.00 | 10/01/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647388 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,500.00 | 10/01/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647390 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $15,000.00 | 10/01/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647392 |
| Recipient | PFIZER INC. | $940.00 | 09/25/2025 | Covered Recipient Physician | ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802418 |
| Recipient | PFIZER INC. | $330.00 | 09/25/2025 | Covered Recipient Physician | ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228803053 |
| Recipient | PFIZER INC. | $3,200.00 | 09/22/2025 | Covered Recipient Physician | ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802424 |
| Principal investigator 1 | H. Lundbeck A S | $1,881.95 | 09/18/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251774844 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 09/18/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289012 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 09/18/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289014 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 09/18/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289016 |
| Principal investigator 1 | H. Lundbeck A S | $5,007.45 | 09/12/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251774627 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/11/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307135 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/11/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307137 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/11/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307139 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/11/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307141 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/11/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307143 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 09/11/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307145 |
| Principal investigator 1 | H. Lundbeck A S | $3,354.00 | 09/10/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774514 |
| Principal investigator 1 | H. Lundbeck A S | $2,534.00 | 09/10/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774517 |
| Principal investigator 1 | H. Lundbeck A S | $631.00 | 09/10/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774521 |
| Principal investigator 1 | H. Lundbeck A S | $2,625.00 | 09/10/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774525 |
| Principal investigator 1 | GENZYME CORPORATION | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity Ki Health Partners Llc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226092219 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293163 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293165 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293167 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293169 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293171 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293173 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293175 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293177 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293179 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293181 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293183 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293185 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293187 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293191 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293193 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293195 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293197 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293199 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293201 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293203 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293205 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293207 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 08/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293213 |
| Principal investigator 1 | PFIZER INC. | $5,100.99 | 08/27/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228826803 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 08/26/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1202505787 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 08/14/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1202504627 |
| Principal investigator 1 | ABBVIE INC. | $9,000.00 | 08/14/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease | No dispute reported | 06/30/2026 | 1202504629 |
| Principal investigator 1 | H. Lundbeck A S | $13,769.30 | 08/14/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251773602 |
| Principal investigator 1 | Ipsen Innovation | $10,000.00 | 08/14/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293189 |
| Principal investigator 1 | Ipsen Innovation | $2,000.00 | 08/14/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293211 |
| Principal investigator 1 | Genentech, Inc. | $12,000.00 | 08/13/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211619888 |
| Principal investigator 1 | Ipsen Innovation | $1,500.00 | 08/13/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293161 |
| Principal investigator 1 | Ipsen Innovation | $1,500.00 | 08/13/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293209 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $14,253.00 | 08/11/2025 | Non-covered Recipient Entity Ki Health Partners LLC | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647400 |
| Principal investigator 1 | Genentech, Inc. | $16,000.00 | 08/08/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211619895 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,171.50 | 08/08/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307113 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,171.50 | 08/08/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307115 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,171.50 | 08/08/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity | No dispute reported | 06/30/2026 | 1184307117 |
| Principal investigator 1 | ABBVIE INC. | $15,995.00 | 08/06/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202502436 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 07/31/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288998 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/31/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289010 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293081 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293083 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293085 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293087 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293107 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293109 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293111 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293113 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293115 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293117 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293119 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 07/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293121 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293077 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293079 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293089 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 07/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293123 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 07/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293125 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 07/24/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202499592 |
| Principal investigator 1 | H. Lundbeck A S | $4,741.45 | 07/22/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251772764 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/22/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289004 |
| Principal investigator 1 | Genentech, Inc. | $3,620.00 | 07/21/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211619883 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $12,500.00 | 07/18/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | ACP-204-006 | No dispute reported | 06/30/2026 | 1245935329 |
| Principal investigator 1 | H. Lundbeck A S | $4,347.00 | 07/17/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251772380 |
| Principal investigator 1 | Ipsen Innovation | $2,000.00 | 07/17/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293095 |
| Principal investigator 1 | Ipsen Innovation | $10,000.00 | 07/17/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293097 |
| Principal investigator 1 | H. Lundbeck A S | $11,500.00 | 07/16/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772360 |
| Principal investigator 1 | H. Lundbeck A S | $3,000.00 | 07/16/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772364 |
| Principal investigator 1 | UPSHER-SMITH LABORATORIES LLC | $4,471.60 | 07/16/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH | P255-501 | No dispute reported | 06/30/2026 | 1253059786 |
| Principal investigator 1 | UPSHER-SMITH LABORATORIES LLC | $2,205.00 | 07/16/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH | P255-501 | No dispute reported | 06/30/2026 | 1253059792 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/15/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289006 |
| Principal investigator 1 | Ipsen Innovation | $270.00 | 07/15/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289008 |
| Principal investigator 1 | Ipsen Innovation | $1,800.00 | 07/14/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293099 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 07/08/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289000 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/08/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289002 |
| Principal investigator 1 | ABBVIE INC. | $1,227.50 | 07/02/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202495271 |
| Principal investigator 1 | ABBVIE INC. | $4,060.00 | 07/02/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202495443 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292917 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292919 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292921 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292923 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292925 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292927 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292929 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292943 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292945 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292947 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292949 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292951 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292953 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292955 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292957 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292959 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292961 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292963 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292965 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292967 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292969 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292971 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292973 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292981 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292983 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292985 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292987 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292989 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292991 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292993 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292995 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292997 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292999 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293001 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293003 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293005 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293007 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293009 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293011 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293013 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293015 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293017 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293019 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293021 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293023 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293025 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293027 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293029 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293031 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293033 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293035 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293037 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293041 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293043 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293045 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293047 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293049 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293051 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293053 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293055 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293057 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293059 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293061 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293063 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293065 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293067 |
| Principal investigator 1 | Ipsen Innovation | $3,430.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293069 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293071 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293073 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 06/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184293075 |
| Principal investigator 1 | Genentech, Inc. | $13,500.00 | 06/24/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211619876 |
| Principal investigator 1 | H. Lundbeck A S | $5,007.45 | 06/24/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251771531 |
| Principal investigator 1 | H. Lundbeck A S | $2,500.00 | 06/24/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251771536 |
| Principal investigator 1 | H. Lundbeck A S | $1,500.00 | 06/24/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251771540 |
| Principal investigator 1 | H. Lundbeck A S | $11,500.00 | 06/24/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251771544 |
| Principal investigator 1 | PFIZER INC. | $10,618.89 | 06/13/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228829673 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 06/12/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288996 |
| Principal investigator 1 | ABBVIE INC. | $927.50 | 06/11/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202490881 |
| Principal investigator 1 | ABBVIE INC. | $4,060.00 | 06/11/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202490883 |
| Principal investigator 1 | H. Lundbeck A S | $9,952.20 | 06/05/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770771 |
| Principal investigator 1 | Ipsen Innovation | $450.00 | 05/23/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288992 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 05/23/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288994 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,000.00 | 05/22/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS, LLC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190308688 |
| Principal investigator 1 | ABBVIE INC. | $2,250.00 | 05/21/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202485611 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 05/21/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202485613 |
| Principal investigator 1 | ABBVIE INC. | $14,602.00 | 05/07/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202482631 |
| Principal investigator 1 | UPSHER-SMITH LABORATORIES LLC | $756.00 | 05/01/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH | P255-501 | No dispute reported | 06/30/2026 | 1253059796 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/30/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292853 |
| Principal investigator 1 | H. Lundbeck A S | $11,311.65 | 04/28/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769869 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292739 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292741 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292743 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292745 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292747 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292749 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292751 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292753 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292755 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292757 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292759 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292761 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292763 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292765 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292767 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292769 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292771 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292773 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292775 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292777 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292779 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292781 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292783 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292785 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292787 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292789 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292791 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292793 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292795 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292797 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292799 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292801 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292803 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292805 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292807 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292809 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292811 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292813 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292815 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292817 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292819 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292821 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292823 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292825 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292827 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292829 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292831 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292833 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292835 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292837 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292839 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292841 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292843 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292845 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292847 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292849 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292851 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292855 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292857 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292859 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292861 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292863 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292865 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292867 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292869 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292871 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292873 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292875 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292877 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292879 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292881 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292883 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292885 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292887 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292889 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292891 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292893 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292895 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292897 |
| Principal investigator 1 | Ipsen Innovation | $4,970.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292899 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292901 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292903 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292905 |
| Principal investigator 1 | Ipsen Innovation | $4,900.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292907 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292909 |
| Principal investigator 1 | Ipsen Innovation | $4,060.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292911 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292913 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 04/28/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292915 |
| Principal investigator 1 | PFIZER INC. | $919.80 | 04/24/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228832370 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 04/21/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288982 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 04/21/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288984 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 04/21/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288986 |
| Principal investigator 1 | Ipsen Innovation | $450.00 | 04/18/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288988 |
| Principal investigator 1 | Ipsen Innovation | $600.00 | 04/18/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288990 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $8,402.00 | 04/10/2025 | Non-covered Recipient Entity Ki Health Partners LLC | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647398 |
| Principal investigator 1 | Ipsen Innovation | $600.00 | 04/09/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288976 |
| Principal investigator 1 | Ipsen Innovation | $360.00 | 04/09/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288978 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 04/09/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288980 |
| Principal investigator 1 | H. Lundbeck A S | $5,007.45 | 04/08/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769478 |
| Recipient | ABBVIE INC. | $230.64 | 04/02/2025 | Covered Recipient Physician | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202399858 |
| Recipient | ABBVIE INC. | $6.16 | 04/02/2025 | Covered Recipient Physician | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202399861 |
| Recipient | ABBVIE INC. | $141.67 | 04/02/2025 | Covered Recipient Physician | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202399867 |
| Recipient | ABBVIE INC. | $32.44 | 04/02/2025 | Covered Recipient Physician | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202399872 |
| Recipient | ABBVIE INC. | $216.34 | 04/02/2025 | Covered Recipient Physician | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202399876 |
| Recipient | ABBVIE INC. | $30.88 | 04/02/2025 | Covered Recipient Physician | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202399881 |
| Principal investigator 1 | UPSHER-SMITH LABORATORIES LLC | $750.00 | 03/26/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH | P255-501 | No dispute reported | 06/30/2026 | 1253059750 |
| Principal investigator 1 | Eli Lilly and Company | $514.50 | 03/25/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187885622 |
| Principal investigator 1 | Eli Lilly and Company | $6.00 | 03/23/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | No dispute reported | 06/30/2026 | 1187883972 |
| Principal investigator 1 | PFIZER INC. | $5,671.59 | 03/13/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228831232 |
| Principal investigator 1 | H. Lundbeck A S | $11,645.10 | 03/11/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251768615 |
| Principal investigator 1 | ABBVIE INC. | $13,295.00 | 03/06/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202457706 |
| Principal investigator 1 | H. Lundbeck A S | $12,606.30 | 03/04/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251768048 |
| Principal investigator 1 | Eli Lilly and Company | $305.20 | 02/25/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885784 |
| Principal investigator 1 | Genentech, Inc. | $3,620.00 | 02/18/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC ENGLAND INSTITUTE FOR CLINICAL RESE | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211619879 |
| Principal investigator 1 | ABBVIE INC. | $6,030.00 | 02/05/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | No dispute reported | 06/30/2026 | 1202445621 |
| Principal investigator 1 | H. Lundbeck A S | $4,347.00 | 02/05/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766999 |
| Principal investigator 1 | Eli Lilly and Company | $135,321.00 | 02/04/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187885786 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 01/31/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292731 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $33,365.94 | 01/31/2025 | Non-covered Recipient Entity NEW ENGLAND INSTITUTE FOR NEUROLOGY AND HEADACHE | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190307559 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $8,359.15 | 01/27/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235995401 |
| Principal investigator 1 | Eli Lilly and Company | $8,275.14 | 01/27/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187883970 |
| Principal investigator 1 | Ipsen Innovation | $3,850.00 | 01/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292733 |
| Principal investigator 1 | Ipsen Innovation | $175.00 | 01/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292735 |
| Principal investigator 1 | Ipsen Innovation | $1,855.00 | 01/27/2025 | Non-covered Recipient Entity Ki Health Partners, Llc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184292737 |
| Principal investigator 1 | Ipsen Innovation | $1,050.00 | 01/23/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288972 |
| Principal investigator 1 | Ipsen Innovation | $270.00 | 01/23/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288974 |
| Principal investigator 1 | PFIZER INC. | $3,843.90 | 01/23/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228831283 |
| Principal investigator 1 | Eli Lilly and Company | $25,201.00 | 01/21/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885620 |
| Principal investigator 1 | Ipsen Innovation | $720.00 | 01/20/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288968 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 01/20/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288970 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $159,125.00 | 01/16/2025 | Non-covered Recipient Entity New England Institute For Neurology And Headache | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235995399 |
| Principal investigator 1 | PFIZER INC. | $4,984.89 | 01/16/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228831276 |
| Principal investigator 1 | PFIZER INC. | $17,549.57 | 01/16/2025 | Non-covered Recipient Entity Ki Health Partners LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228831334 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $281,634.25 | 01/15/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | Efficacy, Safety and Tolerability of Lumateperone in Inadequately Controlled Migraine Patients with and without Comorbid Bipolar Disorder or Depression | No dispute reported | 06/30/2026 | 1242328703 |
| Principal investigator 1 | Eli Lilly and Company | $143,954.00 | 01/08/2025 | Non-covered Recipient Entity KI HEALTH PARTNERS LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187883968 |
| Principal investigator 1 | H. Lundbeck A S | $5,639.20 | 01/07/2025 | Non-covered Recipient Entity KI CLINICAL RESEARCH | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766252 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $4,227.00 | 01/06/2025 | Non-covered Recipient Entity Ki Health Partners LLC | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647396 |